Pulmonology
MedStar Health provides both inpatient and outpatient services to diagnose and treat breathing diseases and disorders. In our pulmonary function laboratories, sophisticated diagnostic testing helps doctors evaluate lung function.
Our pulmonary medicine physicians provide state-of-the-art clinical evaluation, diagnosis, and treatment for disorders of the respiratory system.
Our transdisciplinary team of pulmonologists, surgeons, nurses, oncologists, respiratory therapists, and other specialists offer a unique blend of services not available at any other institution or practice in the region.
A multidisciplinary approach
Outpatient diagnostic testing and care management are also provided to patients through the Ambulatory Care Center—and in our physicians’ private offices.
The team routinely works in collaboration with many other specialists on the medical staff in an integrated, multidisciplinary approach to patient care.
Advanced interventional pulmonology
Interventional pulmonology is a relatively new field that uses endoscopy and other tools to diagnose and treat conditions in the lungs and chest.
Clinical trials
-
Bronchiectasis/NTM Current Clinical Trials
Dr. Anne O’Donnell
Bronchiectasis Research Registry [COPD Foundation]
A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis BronchiectasisRPL554-NCFB-220
Sponsor: Verona PharmaMultiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections-CLAM320B2002M
Sponsor: NovartisICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B) MKC-CI-002
Sponsor: MannKind -
Idiopathic Pulmonary Fibrosis/ Progressive Pulmonary Fibrosis
Dr. Cristina Reichner and Dr. Christine Fleury
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis (REVERT Trial)
Sponsor: Tvardi TherapeuticsA randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
Sponsor: Pliant TherapeuticsA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON IPF)
Sponsor: United TherapeuticsA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
Sponsor: United TherapeuticsA Study To Evaluate The Efficacy, Safety, And Tolerability Of BMS-986278 In Participants With Idiopathic Pulmonary Fibrosis (IM027068-ALOFT IPF)
Sponsor: Bristol Myers SquibbA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis (IMS1015- ALOFT PPF)
Sponsor: Bristol Myers Squibb -
Cough
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Sponsor: Bellus Health